Genocea Revenue and Competitors

Boston, MA USA

Location

$470.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Genocea's estimated annual revenue is currently $15.5M per year.(i)
  • Genocea received $55.0M in venture funding in January 2018.
  • Genocea's estimated revenue per employee is $155,000
  • Genocea's total funding is $470.6M.

Employee Data

  • Genocea has 100 Employees.(i)
  • Genocea grew their employee count by -21% last year.

Genocea's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Genocea?

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.

keywords:Biotechnology,Enterprise Software,Healthcare,Pharmaceuticals

$470.6M

Total Funding

100

Number of Employees

$15.5M

Revenue (est)

-21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Genocea News

2022-04-20 - Genocea stock slips on cutting workforce by 65% and ...

Genocea Biosciences (NASDAQ:GNCA) has initiated a process to explore a range of strategic alternatives to maximize shareholder value,...

2022-04-20 - Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives

Genocea's mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer.

2021-10-28 - GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T - Form 8-K

GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., October 28, 2021 - Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-gen ...

2021-07-29 - Genocea Biosciences : Provides Second Quarter 2021 Corporate Update

GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GEN-009 neoantigen vaccine candidate shows promising long-term clinical results Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), ...

2021-04-29 - GENOCEA BIOSCIENCES, INC. Genocea Biosciences : Provides First Quarter 2021 Corporate Update

GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens™ and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company deve ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$21.4M100-27%$525.5M
#2
$25.1M10020%N/A
#3
$16M1006%N/A
#4
$22M1011%$478.3M
#5
$15.7M101-16%$380.7M

Genocea Funding

DateAmountRoundLead InvestorsReference
2009-02-20$23.0MASR OneArticle
2011-01-04$35.0MSecondJohnson & Johnson Development , Skyline VenturesArticle
2012-10-11$30.0MCThe Bill & Melinda Gates Found, CVF LLCArticle
2013-10-16$0.4MUndisclosedArticle
2014-11-24$27.0MUndisclosedHercules Technology Growth CapitalArticle
2015-03-13$51.7MUndisclosedCowen and CompanyArticle
2015-07-31$57.6MUndisclosedMultipleArticle
2018-01-18$55.0MUndisclosedCantor Fitzgerald & CoArticle